The authors have demonstrated that bortezomib treatment activates autophagy in MM CAFs by inhibiting mTOR, inducing LC3- II, and activating the transforming growth factor beta (TGF-β) pathway [64]. The gene discussed is MTOR; the disease is Miyoshi myopathy.